オプションチェーンは、Sonnet BioTherapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Sonnet BioTherapeuticsの市場センチメントを評価します。.

Sonnet BioTherapeutics (NASDAQ:SONN) 株価情報, オプションチェーン

Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics Holdings Inc

The company remains on track for a topline Phase 1 data readout by the end of the year.

Biotech

News

General

SABS

SAB BIO Says Co Completed Phase 1 Enrollment For SAB-142 With No Observation Of Serum Sickness

Earnings

SAB BIO Q3 2024 Cash, Cash Equivalents Available $30.4M-$56.6M

Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.82) by 8.54 percent. The company reported quarterly sales of $7.658 million which missed the analyst consensus estimate of $10.598 million by 27.74 percent. This is a 61.55 percent decrease over sales of $19.915 million the same period last year.

Earnings Beats

Earnings Misses

GPMT

Granite Point Mortgage Q3 2024 Adj. EPS $(0.75) Beats $(0.82) Estimate, Sales $7.658M Miss $10.598M Estimate

Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 62.5 percent decrease over losses of $(0.08) per share from the same period last year.

TRVI

Trevi Therapeutics Q3 2024 GAAP EPS $(0.13) Misses $(0.12) Estimate

VIRX

Viracta Therapeutics To Reprioritize Resources To Focus On Nana-val Development Program In Relapsed Or Refractory EBV-Positive Peripheral T-Cell Lymphoma; Announces 42% Force Reduction, Sees $700K In Total Expenses

Ardent Health Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.30 by 36.67 percent. The company reported quarterly sales of $1.45 billion which met the analyst consensus estimate. This is a 5.22 percent increase over sales of $1.38 billion the same period last year.

ARDT

Ardent Health Partners Q3 2024 GAAP EPS $0.19 Misses $0.30 Estimate, Sales $1.45B Inline

Offerings

ALKT

Alkami Launches Proposed Secondary Offering Of 7.5M Shares

Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares are up after the company reported its third-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41786518/dutch-bros-inc-reports-third-quarter-2024-financial-results">details from the report.</a>
The Details: Dutch Bros reported quarterly earnings of 16 cents per share, which beat the analyst consensus estimate of 12 cents. Quarterly revenue came in at $338.21 million, which beat the analyst consensus estimate of $325.14 million and is an increase over sales of $264.51 million from the same period last year.
<ul>
<li>Dutch Bros opened 38 new shops, 33 were company-operated, across 11 states.</li>
<li>System same-shop sales and transactions increased 2.7% and 0.8%, respectively, relative to the same period in 2023.</li>
<li>Company-operated same-shop sales and transactions increased 4% and 2.4%, respectively, relative to the same period of 2023.</li>
<li>Company-operated shop revenues increased 30.4% to $308.3 million, as compared to $236.5 million in the same period last year. </li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;We delivered exceptional performance in the third quarter as we executed our strategic and operational initiatives. We believe our brand is resonating with customers, as we had the highest same-shop transaction growth quarter in two years, outside of the impact of Leap Day. In the third quarter we delivered a 28% revenue increase and systemwide same-shop sales growth of 2.7%, which exceeded our expectations,&#8221; said Christine Barone, CEO of Dutch Bros.
Outlook:&nbsp;The company raised its fiscal year total revenues to be between $1.255 billion and $1.26 billion, up from the prior range of $1.215 billion to $1.23 billion.
BROS Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Dutch Bros shares are up 15.20% after-hours at $40.25 at the time of publication Wednesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Courtesy of Dutch Bros Inc.

Restaurants

After-Hours Center

Movers

BROS

Dutch Bros Stock Perks Up After Solid Q3 Earnings Report: Details

Manulife Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFC#NYSE">MFC</a>) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $0.94 by 6.38 percent. The company reported $1.800 billion in sales this quarter. This is a 35.44 percent increase over sales of $1.329 billion the same period last year.

Manulife Financial Q3 2024 Adj. EPS $1.00 Beats $0.94 Estimate, Sales $1.800B Up From $1.329B YoY

Guidance

Marathon Oil Raises 2024 Total Oil Production Guidance To 192,000 Net Bopd And Oil Equivalent Guidance To 393,000 Net Boed, While Leaving Original Capital Spending Guidance Range Unchanged

Kronos Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRO#NYSE">KRO</a>) reported quarterly sales of $484.70 million which missed the analyst consensus estimate of $569.54 million by 14.90 percent. This is a 22.12 percent increase over sales of $396.90 million the same period last year.

Kronos Worldwide Q3 Sales $484.70M Miss $569.54M Estimate

Iochpe-Maxion (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IOCJY#OTC">IOCJY</a>) reported quarterly earnings of $0.04 per share. This is a 53.85 percent increase over earnings of $0.03 per share from the same period last year. The company reported $717.89 million in sales this quarter. This is a 4.59 percent decrease over sales of $752.42 million the same period last year.

IOCJY

Iochpe-Maxion Q3 EPS $0.04 Up From $0.03 YoY, Sales $717.89M Down From $752.42M YoY

PAHC

CORRECTION: Phibro Animal Health Q1 2025 Adj. EPS $0.35 Beats $0.25 Estimate, Sales $260.400M Beat $244.400M Estimate

Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. The company reported quarterly sales of $118.728 million which missed the analyst consensus estimate of $125.849 million by 5.66 percent. This is a 17.12 percent decrease over sales of $143.259 million the same period last year.

APPS

Digital Turbine Q2 2025 Adj. EPS $0.05 Misses $0.06 Estimate, Sales $118.728M Miss $125.849M Estimate

Fidelity National Financial Says Continues To Make Strong Progress Toward Investor Day Targets

Plymouth Industrial REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLYM#NYSE">PLYM</a>) lowers FY2024 FFO guidance from $1.88-1.90 to $1.83-1.85 vs $1.89 analyst estimate..

PLYM

Plymouth Industrial REIT Lowers FY2024 FFO Guidance from $1.88-1.90 to $1.83-1.85 vs $1.89 Est

Sharpens focus on strategic aerospace and defense markets, streamlines operations
DALLAS, Nov. 6, 2024 /PRNewswire/ -- ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) announced it completed the sale of its precision rolled strip operations in New Bedford, Massachusetts and Remscheid, Germany to Ulbrich Stainless Steels and Special Metals, Inc. (Ulbrich).

Asset Sales

ATI Announces Sale Of Precision Rolled Strip Operations To Ulbrich Stainless Steels And Special Metals, Inc.; No Financial Terms Disclosed

Upwork Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) shares are climbing after the company reported its third-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g41786339/upwork-reports-third-quarter-2024-financial-results">key figures from the report. </a>
The Details: Upwork reported quarterly earnings of 29 cents per share, which beat the analyst consensus estimate of 26 cents. Quarterly revenue came in at $193.8 million, which beat the analyst consensus estimate of $185.85 million and is an increase over sales of $175.73 million from the same period last year.
<ul>
<li>Active clients grew 2% year-over-year to 855,000. </li>
<li>Free cash flow was $98 million in the third quarter of 2024, compared to free cash flow of $33.4 million in the third quarter of 2023. </li>
<li>Managed Services grew revenue 5% year-over-year in the third quarter, reflecting increasing demand for delivery of work outcomes and strong pipeline of new Managed Services clients.</li>
<li>Freelancer Plus subscription revenue increased 48% year-over-year in the third quarter.</li>
</ul>
The company also announced a $100 million share repurchase program. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;Upwork continues to seize the tremendous market opportunity and execute our strategy to deliver durable, profitable growth, with 10% year-over-year revenue growth and our highest-ever net income in the third quarter,&#8221; said Hayden Brown, president and CEO of Upwork.
&#8220;We are building long-term shareholder value by serving clients with work outcomes on demand, produced by the world&#8217;s most skilled freelance professionals working hand-in-hand with cutting-edge AI tools. This quarter, our AI-powered innovation accelerated, with new capabilities for Uma, Upwork&#8217;s Mindful AI, that streamline key steps in matching with and hiring talent as well as delivering outcomes in both our Marketplace and Managed Services offerings,&#8221; Brown added. 
Outlook:&nbsp;Upwork sees fourth-quarter revenue of between $178 million and $183 million and adjusted earnings of between 24 cents and 28 cents per share. 
UPWK Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Upwork shares are up 8.92% after-hours at $15.88 at the time of publication Wednesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Pete Linforth from Pixabay

UPWK

Upwork Shares Higher After Q3 Earnings Beat, Raised Guidance, $100M Stock Buyback

CompX International Q3 Revenue $33.6M Vs $40.3M YoY; GAAP EPS $0.28 Vs $0.47 YoY

ESGR

Enstar Shareholders Approve Sixth Street Acquisition; Terms Not Disclosed

Warning: SONN is at high risk of performing badly

Sonnet BioTherapeutics (SONN) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,134,635 entitled "...

Sonnet BioTherapeutics announces USPTO issued U.S. patent on IL-18

The latest announcement is out from Sonnet BioTherapeutics Holdings ( ($SONN) ). Sonnet BioTherapeutics has secured a U.S. patent for two innovativ...

Sonnet BioTherapeutics Secures Patent for Cancer Drugs

Sonnet BioTherapeutics (SONN) Holdings announced the pricing of an underwritten public offering of 1.11M shares of common stock and common warrants...

Sonnet BioTherapeutics prices $5M at-the-market offering

SONN

Contracts

Press Releases

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Comments

Sonnet BioTherapeutics

Sonnet BioTherapeutics (SONN) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル